Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery

Rare diseases. Patient advocacy. Drug development. FDA partnerships. Clinical trials.Patient organizations have evolved into powerful engines of drug development, building registries, funding research, shaping clinical trial design, and partnering with regulators to accelerate new treatments.This week on the Making Medicine Podcast, John Stanford sits down with Lisa Bonebrake, Executive Director of the Alport Syndrome Foundation, and Janis Naeve, world-class VC and Co-Founder & Partner of Bright Frontier, to discuss the evolving, high-impact role of patient organizations in modern drug development.Patient advocacy groups are building the critical data and clinical infrastructure required to advance medical research. Lisa shares how the Alport Syndrome Foundation is directly de-risking clinical trials, building global patient registries, and driving the ASCENT Initiative, a historic public-private partnership with the FDA to establish surrogate endpoints for kidney disease.The discussion also explores the venture capital perspective with Janis Naeve, highlighting why investors view patient-led data infrastructure as a "highway" for innovation, how pharmaceutical companies can successfully integrate patient feedback into trial design, and why establishing clear regulatory pathways is vital to accelerating rare disease treatments.This Episode Covers🔹 Why patient advocacy groups are the new infrastructure of drug discovery🔹 The real impact of Alport syndrome and the importance of early genetic testing🔹 The ASCENT Initiative and establishing surrogate endpoints with the FDA🔹 The impact of Alport syndrome and the importance of early genetic testing🔹 Why pharmaceutical companies must include patient voices in clinical trial design 🔹 The venture capital perspective on funding rare disease innovation🔹 Regulatory clarity and de-risking biotech investment🔹 How public-private partnerships accelerate the timeline for lifesaving treatmentsPatient advocates are no longer passive charities, they are the essential infrastructure of modern drug discovery. This conversation serves as a blueprint for the future of healthcare policy, exploring how rare disease organizations are partnering with the FDA, saving pharma millions by rescuing flawed clinical trials, and driving venture capital investment to accelerate lifesaving treatments.Join the Conversation⬇️ Should patient organizations have a larger role in shaping FDA regulatory pathways? What's the biggest obstacle preventing more rare disease drug development? How can policymakers better support patient-led research infrastructure?Let us know your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true👍 Like and subscribe for more biotech and healthcare policy coverage.Timestamps0:00 - The Real ROI of Patient Advocacy0:26 - Welcome to the Making Medicine Podcast1:52 - Breaking News in Alport Syndrome Research4:03 - What is Alport Syndrome? 5:58 - Redefining the Role of Patient Organizations9:09 - A VC Investor’s Perspective on Rare Disease11:38 - The ASCENT Initiative & FDA Public-Private Partnership18:03 - Understanding Surrogate Endpoints in Clinical Trials25:19 - How to Build a Fearless Patient Advocacy Group30:26 - Why Pharma Needs to Listen Directly to Patients35:31 - Educating the Biotech Industry on Patient Integration39:35 - Key Takeaways for Policymakers and InvestorsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#rarediseases #drugdevelopment #clinicaltrials #fda #biotech #patientadvocacy #makingmedicine #podcast